The article highlights that Coherus BioSciences has received mostly bullish analyst ratings in the last quarter. The average 12-month price target has increased by 1.85% from the previous average, indicating a positive outlook for the stock. This information is relevant and important for investors, as it suggests a potential increase in stock price in the short term.